$30,000/day still going to Pharmathene. Siga management and it's cohorts are pocketing how much a day while this continues? Siga shareholders looking at their ROI flying out the window. Siga management doesn't seem to have any concern of ever actually returning anything to shareholders.
One in a million. A post on long term implications. Wish there were boards for traders and one for investing
...beat expectations on EBITDA distributable cash flows in August
* Must be forced selling and share liquidations of anything oil related bringing down the good along with the bad and the ugly.
Judge Parsons has an impressive background and many years of dealing with complicated cases. Judge Parsons got guidelines from DSC and to to take a closer look while using the most qualified specialist to determine the settlement. Parsons went way conservative to find what would be the case in Siga's Layers expertise.
versus ya-ya opinions on this board. Did you pick up PIP shares at lower prices? I did. Would I hire you or Judge Parsons for legal advice? HA!!!
Dec 20, 2006
VaxGen Inc. said late Tuesday that the Department of Health and Human Services (HHS) has terminated the company's $877.5 million contract to provide 75 million doses of a modern anthrax vaccine for civilian biodefense.
Brisbane-based VaxGen (Pink Sheets:VXGN) said HHS based the decision on its determination that VaxGen "failed to successfully cure the condition endangering performance" and failed to meet a milestone imposed by HHS that required VaxGen to initiate a clinical trial of the vaccine candidate by Dec. 18.
($877.5 million) - looking forward to the next quarterly conference call.
then the trial with Sparvax added to Depovax and the survival results:
Rabbits were exposed to a lethal dose of the anthrax causing bacterial spores (B. anthracis) 28 days following a single vaccination. The DepoVax/rPA vaccines provided good protection to animals against anthrax with a single dose, protecting a total of 15 of 24 animals across the three different rPA sources. As expected, control animals injected with a saline solution all succumbed to the anthrax challenge. Animals given a placebo DepoVax vaccine with no antigen also succumbed to anthrax, demonstrating that protection is mediated by the combination of DepoVax and rPA
Preliminary findings from the immunogenicity studies include:
• A single dose of DepoVaxTM-formulated anthrax vaccine produced sustained toxin-neutralizing antibody (“TNA”) titers detected in six of ten animals, starting between day 21 and 49. Animals receiving one dose of Biothrax had no detectable TNA titers.
• When a second dose of the DepoVaxTM-formulated vaccine was delivered, there was a significant increase in anthrax TNAs in all immunized animals within one week of the booster administration
There are so many billion dollar valued companies pumped up by ETF's and short squeezing. As long as fresh money sees no other sector that can be hyped like Bio it's to the moon Alice.
Google the generics drugs that have gone up in price by 5-7 times their original price in the last couple of years. Buyouts and their games in the medical field.
K Street, The AMA , Biopharma are becoming known as the Medical Industrial Complex. Someone let me know when nosebleed is reached.
Furthermore, this Court enjoys remedial flexibility to depart from strict application of the ordinary forms of relief where circumstances require.30 Nevertheless, courts of equity should attempt to balance that flexibility by a measure of concomitant restraint to
Forced selling and lack of buyers is what crashed the entire market into the entry of a lifetime. Looks like AUY is heading there. A few months of below $900 gold will BK a lot of marginal players unable to handle debt loads.
How long will it take for buyers to creep back into oil? First "real" sign of inflation which may be a couple years off.
The Supremes advised Parson's to use best expert opinion on this type of dispute to determine the award. That is where Parsons went way conservative and ended up with $130M that has nothing near the billions both parties thought -246 was worth in Sept '06. With interest adding $30,000 daily to the ill intent boyz liability we can all hope this comes to an end soon.
GLTA, but the boyz (they have already pocketed tens of millions in the money flow and cost of goods, more than they deserve)
the Supreme Court held that “where the parties have a Type II preliminary agreement to negotiate in good faith, and the trial judge makes a factual finding, supported by the record, that the parties would have reached an agreement but for the defendant’s bad faith negotiations, the plaintiff is entitled to recover contract expectation damages.” Further, the court found that the factual conclusions made by the Court of Chancery support a finding that the LATS was a Type II preliminary agreement and that SIGA and Pharmathene could not, in good faith, propose terms of the definitive licensing agreement that were inconsistent with the LATS. Because this was the first time the Delaware Supreme Court addressed whether Delaware law recognizes Type II preliminary agreements or whether a plaintiff is entitled to recover expectation damages in connection with a breach of an obligation to negotiate a definitive agreement in good faith, the Supreme Court reversed the Court of Chancery’s damages award for reconsideration consistent with its ruling.
DSC is looking at a filthy rich man that remotely cares about the investors that should be the core of what our financial system should be working for. ILL WILL for everyone but the rich.
From July '14 CC
* $8 million in the fiscal year ended March 31, 2013 (Mevion is in an impressive growth trajectory with 5 sites now under construction)
* It’s a very efficient use of our capacity. (nice margins?)
* What we really need to see is all five of those next units going in earnest at a good pace that really fills Ranor’s capacity. And if we get up into the high eight figures meaning that the loaded mid-teens, we then really have to think about balancing our capacity at Ranor to host that type of volume from Mevion.
* So again we work with them over a two to five year planning horizon which is the life span of that exclusive supply agreement we are in with them. And we try to make sure we can have the capacity available with our other customers and with the additional load on the Ranor facility.
LITTLETON, MASS., August 4, 2015 – Mevion Medical Systems, the leading provider of advanced proton therapy systems, announced today that it has entered into an investment agreement where up to $200 million will be invested in Mevion to accelerate its worldwide expansion.
Note that last July TechPrecision mentioned the concern of capacity to fulfill Mevion obligations and satisfy existing customers.
I'm guessing the run on this stock could be HUGE as Mevion may be accelerating.
Beat on the lowered (multiple time during quarter) earnings, loss actually. After CC the estimates for next quarter have already been lowered, again. Then there was the Q&A and it sounds like dilution was the word they danced around.
See cash, debt and cash flow. I really think the short position is waiting for a capital raise through dilution.
GLTA small investors.